Blog
RSS FeedPosted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating ...
Posted by Michael Wonder on 23 Jun 2020
The case for using novel value elements when assessing COVID-19 vaccines and therapeutics
23 June 2020 - In the span of mere weeks, the novel coronavirus (COVID-19) has upended modern life. Schools and businesses ...
Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...
Posted by Michael Wonder on 16 Jun 2020
VA and ICER at three years: critics' concerns answered
15 June 2020 - As part of its national formulary management process, the Department of Veterans Affairs (VA) Pharmacy Benefits ...
Posted by Michael Wonder on 15 Jun 2020
COVID-19 and remdesivir: rethinking how we measure a drug’s ‘value’
15 June 2020 - As pharmaceutical and biotech companies scramble to identify treatments for COVID-19, a new disease that initially ...
Posted by Michael Wonder on 12 Jun 2020
ICER to assess treatments for high cholesterol
12 June 2020 - Report will be subject of a Midwest CEPAC meeting in February 2021; ppen Input now being ...
Posted by Michael Wonder on 08 Jun 2020
Fate of pharma’s reputation lies in Gilead’s hands on pricing of COVID-19 drug remdesivir
8 June 2020 - Few remember the time when the pharmaceutical industry was the world’s most admired. ...
Posted by Michael Wonder on 03 Jun 2020
Paying for value from costly medical technologies: a framework for applying value-based payment reforms
2 June 2020 - Innovative medical products offer significant and potentially transformative impacts on health, but they create concerns about rising ...
Posted by Michael Wonder on 02 Jun 2020
Traditional cost effectiveness formulas and precision medicines
1 June 2020 - Cost effectiveness analyses, which are often conducted to evaluate new medicines, use a standardised framework to ...
Posted by Michael Wonder on 26 May 2020
ICER releases draft evidence report on ulcerative colitis therapies
26 May 2020 - Public comment period now open until 29 July 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 21 May 2020
ISPOR holds its first completely virtual conference
21 May 2020 - Virtual ISPOR 2020 plenaries focused on health policy, big data and artificial intelligence, cost effectiveness analysis and ...
Posted by Michael Wonder on 20 May 2020
Valuing and pricing remdesivir: should drug makers get paid for helping us get back to work?
20 May 2020 - On April 29, the National Institutes of Health announced that in a placebo-controlled trial of patients with ...
Posted by Michael Wonder on 20 May 2020
ICER posts draft scoping document for the assessment of supervised injection facilities
19 May 2020 - Document open to public comment until 9 June 2020. ...
Posted by Michael Wonder on 18 May 2020
International reference pricing gets thumbs down from ISPOR panel
18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...
Posted by Michael Wonder on 15 May 2020
Putting a dollar value on life? Governments already do
11 May 2020 - Trade-offs are routine in health policy, and the math and analysis underlying them have been around for ...